Chemomab Therapeutics Ltd. (CMMB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director | 700k | -- | 1982 |
| Ms. Sigal Fattal CPA, M.B.A. | Chief Financial Officer | 500k | -- | 1971 |
| Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer & VP of Drug Development | 777k | -- | 1969 |
| Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications | -- | -- | -- |
| Dr. David M. Weiner M.D. | Interim Chief Medical Officer | -- | -- | 1965 |
| Mr. Jack Lawler | Chief Development Officer | -- | -- | -- |
Chemomab Therapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Corporate Governance
Upcoming Events
August 19, 2025 at 11:00 AM UTC - August 25, 2025 at 11:00 AM UTC
Chemomab Therapeutics Ltd. Earnings Date
Recent Events
December 2, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing